Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10026292 | 0.88 | PRKCA (0.50) | PRKCALMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6370166 | 0.88 | PRKCA (0.50) | PRKCALMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3189263 | 0.85 | PRKCA (0.51) | PRKCALMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10130615 | 0.83 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL19300984 | 0.81 | PRKCA (0.44) | PRKCALMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19300629 | 0.81 | PRKCA (0.56) | PRKCALMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27821634 | 0.80 | TSHR (0.42) | PRKCALMNAMAPTSMN1; SMN2 | |
| SCHEMBL1405394 | 0.79 | LMNA (0.56) | PRKCALMNAALDH1A1SMN1; SMN2PRKCE | |
| SCHEMBL12966322 | 0.78 | LMNA (0.47) | PRKCALMNAALDH1A1SMN1; SMN2PRKCE | |
| SCHEMBL19300995 | 0.76 | PRKCA (0.40) | PRKCALMNAALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771588-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9657294-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9181551-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150267200-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150148530-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2015-05-28 | — | — | US | disclosed |
| US-20120041184-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-7943757-B2 | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) | BANK OF AMERICA, N.A. | 2011-05-17 | — | — | US | disclosed |
| US-7893248-B2 | nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases | SIRNA THERAPEUTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110015251-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | MERCK SHARP & DOHME CORP. | 2011-01-20 | — | — | US | disclosed |
| US-20090264504-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| EP-2042510-A2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleid acid (siNA) | Sirna Therapeutics Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264504-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, EIF2AK2, MAVS | PRKCA 2311/4885LMNA 3976/4885ALDH1A1 3025/4885 |
| US-20120041184-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, EIF2AK2, MAVS | PRKCA 2311/4885LMNA 3976/4885ALDH1A1 3025/4885 |
| US-20110015251-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, EIF2AK2, MAVS | PRKCA 2333/4885LMNA 3988/4885ALDH1A1 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.